Background Despite increased INSTI use, limited large-scale, real-life data exists on INSTI uptake and discontinuation. Setting International multicohort collaboration. Methods RESPOND participants starting dolutegravir (DTG), elvitegravir (EVG) or raltegravir (RAL) after 1/1/2012 were included. Predictors of INSTI used were assessed using multinomial logistic regression. Kaplan Meier and Cox proportional hazards models describe time to and factors associated with discontinuation. Results Overall, 9702 persons were included; 5051 (52.1%) starting DTG, 1933 (19.9%) EVG, 2718 (28.0%) RAL. The likelihood of starting RAL or EVG versus DTG decreased over time and was higher in Eastern and Southern Europe compared to Western Europe. At 6 months after initiation, 8.9% (95% CI 8.3%-9.5%) had discontinued the INSTI (6.4% DTG, 7.4% EVG, 14.0% RAL). The main reason for discontinuation was toxicity (44.2% DTG, 42.5% EVG, 17.3% RAL). Nervous system toxicity accounted for a higher proportion of toxicity discontinuations on DTG (31.8% DTG, 23.4% EVG, 6.6% RAL). Overall, treatment simplification was highest on RAL (2.7% DTG, 1.6% EVG, 19.8% RAL).
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Introduction
Integrase strand transfer inhibitors (INSTIs) are one of the latest antiretroviral drug classes to be approved for use as part of combination antiretroviral therapy (ART) regimens to control HIV 1 . Current HIV treatment guidelines recommend that initial ART regimens for adults include a backbone of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent consisting of an INSTI, boosted protease inhibitor (PI/b) or non-nucleoside reverse transcriptase inhibitor (NNRTI) 2, 3 . There are currently four INSTIs approved by the European Medicines Agency. Raltegravir (RAL) 4, 5 was the first to be approved in 2008, followed by elvitegravir (EVG) 6, 7 in 2013, dolutegravir (DTG) [8] [9] [10] [11] in 2014, and bictegravir (BIC) 12,13 in 2018.
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Commonly reported adverse effects (AEs) associated with INSTIs include headache, nausea, and sleep disturbances 14 . Additionally, cobicistat boosted EVG (EVG/c) and
DTG may cause inhibition of renal tubular secretion of creatinine, causing an artefactual increase in creatinine plasma levels not reflective of a declining renal function 10, 15, 16 .
Whilst the frequency of drug-drug interactions on INSTIs as a class is relatively low, it is higher on EVG, due to the need for a pharmacokinetic enhancer 2 .
Several randomised controlled trials (RCTs) have demonstrated good virological efficacy, fewer AEs, and lower rates of discontinuation with INSTIs compared to NNRTIs 6, 10, [17] [18] [19] [20] and PI/b 7, 15, [21] [22] [23] [24] . These results have been confirmed in small observational studies 14, 25, 26 . However, despite the growing evidence, limited data exist on the choice of INSTIs and discontinuation of INSTIs in larger and more heterogeneous real-world settings. Access to individual INSTIs and reasons for discontinuation of INSTIs may differ among countries and subgroups, such as males versus females. Additionally, due to their presumed favourable safety profile, it is likely that a higher proportion of those with existing comorbidities are receiving INSTIs.
We aimed to describe the characteristics of those initiating INSTIs for the first time in heterogeneous real-world settings across Europe and Australia. We also aimed to describe time to and reasons for discontinuation of initial INSTI regimens and describe the characteristics of those discontinuing INSTIs.
Methods

Study Design and Participants
The International Cohort Consortium of Infectious Diseases (RESPOND) is a collaboration of 14 observational cohort studies across Europe and Australia, including Individuals were included in this analysis if they had started DTG, EVG/c or RAL (persons were not necessarily ART-naïve) after the latest of local cohort enrolment and 1 st January 2012, were aged ≥ 16, and had a CD4 cell count and viral load (VL) measurement prior to or within 6 months after starting an INSTI. Individuals were excluded from the analysis if they had missing information on gender. Final follow-up in our study was the last clinic visit prior to 2018.
Definition of outcomes
The first outcome was defined as uptake of DTG, EVG/c, or RAL. Individuals starting more than one INSTI during follow-up were included in the first INSTI group they were exposed to. 
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Prespecified subgroup analyses were performed between INSTI type and each of gender, age, HIV risk group, HBV/HCV status, and each comorbidity listed above.
In all analysis models, an unknown category was used to account for missing data for categorical variables. As some cohorts were missing data on specific comorbidities, we did not adjust for cohort in the primary analysis. Sensitivity analyses were performed including cohort as an explanatory variable and excluding comorbidities. Additionally, the models were rerun using multiple imputation by chained equations to account for missing data with 10 imputations, including the same variables as those included in the primary analysis model. Results were combined using Rubin's rules.
Analyses were performed using Stata/SE 15.0. P-values are two sided and a p-value <0.05 was defined as statistically significant.
Results
Overall, 10,366 participants in RESPOND started an INSTI and of these, 9,702 (93.6%) were included in the analysis. Reasons for exclusion from the analysis are presented in was also associated with a decreased likelihood of starting EVG/c. The likelihood of starting RAL was higher for participants who were ART-naïve or ART-experienced with ongoing viremia compared to those who were ART-experienced with a suppressed VL. In general, participants with comorbidities were more likely to start RAL but less likely to start EVG/c compared to DTG ( Table 2 ). Adjusting additionally for the nucleoside backbone did not change our findings, except HBV coinfection, which was no longer associated with choice of INSTI.
We found a significant interaction between age and gender (p-value for interaction <0.001) for RAL vs DTG, showing that females were more likely to start RAL compared to men in younger age groups but were less likely to start RAL in older age groups (supplementary Figure 2 , http://links.lww.com/QAI/B408). Other prespecified subgroup analyses were non-significant. Results were stratified by ART experience at baseline with similar findings. We repeated analyses adjusting for cohort instead of comorbidities with similar results. Multiple imputation to account for missing data also showed similar results (data not shown). As a post hoc analysis, we repeated analyses only including those starting an INSTI from 2015 (when DTG, EVG/c and RAL were available) and found similar results. KM plots of discontinuation, overall and by ART-experience are shown in Figure 1 .
Discontinuation of INSTIs
The overall KM estimate of discontinuation at 6 months after INSTI start was 8.9%
(95% CI: 8. 3-9.5) when DTG and EVG/c were both approved.
Reasons for discontinuation overall, within 6 months after INSTI start, and after 6 months after INSTI start are presented in Figure 2a . Of all discontinuations by 6 months, the most commonly reported reason for discontinuation was toxicity (31.4% overall), followed by patient/physician choice (24.6% overall). Reasons for discontinuation were similar for DTG and EVG/c, with toxicity accounting for nearly half of all discontinuations in these groups (44.2% and 42.5% respectively). Conversely, of all discontinuations on RAL, the main reason reported was patient/physician choice (28.6%). Discontinuations for treatment simplification accounted for a considerably higher proportion of discontinuations on RAL compared to DTG or EVG/c (19.8% on RAL, 2.7% on DTG, 1.6% on EVG/c, p<0.001). We also compared reasons for discontinuation between males and females and found similar results.
Discontinuations due to toxicity were further broken down and compared between INSTI types (Figure 2b Factors associated with discontinuation within the first 6 months are presented in Figure   3 . We found no evidence that the association between risk of discontinuation by 6 months and INSTI type differed according to ART-experience (p-value for interaction 0.51).
Prespecified subgroup analyses showed a significant interaction between INSTI type and age group, shown in supplementary Figure 3 , http://links.lww.com/QAI/B408 (pvalue for interaction 0.001). Across all age groups, the risk of discontinuation was higher on RAL than on DTG; however, the difference between RAL and DTG decreased slightly in older age groups. There was an increased risk of discontinuation of EVG/c compared to DTG in the oldest age group (≥50 years); however, there was no difference in the risk in lower age groups.
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Discussion
To the best of our knowledge, this is one of the first, large-scale studies investigating uptake Subgroup analyses of INSTI uptake showed that females were more likely to start RAL compared to males in lower age groups but were less likely to start RAL in older age groups. This may partly be because RAL is recommended in treatment guidelines for pregnant women (or women wishing to conceive), in particular those starting follow-up late or whose VL is not fully suppressed at the third trimester 2, 29 . In older age groups, treatment simplification may be a higher priority for menopausal women; therefore, regimens containing DTG are likely to be favoured over RAL.
Furthermore, our analysis showed that those with HBV coinfection were more likely to start RAL or EVG/c, and those with prior CVD were also more likely to start RAL compared to DTG. Treatment guidelines recommend using a TDF or tenofovir alafenamide containing regimen in HBV coinfected individuals 2, 30, 31 . After adjustment for NRTI backbone the association between HBV and choice of INSTI was no longer significant, suggesting the backbone was likely driving this treatment choice rather than the INSTI. ABC has been associated with an increased risk of CVD and is commonly prescribed with DTG 32 . However, after adjusting for backbone, the association between CVD and the likelihood of starting RAL remained highly significant suggesting this decision was not driven by ABC.
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During follow up, the risk of discontinuation was significantly higher on RAL compared to DTG or EVG/c, mainly due to treatment simplification. We found the rate of discontinuation on RAL was higher than reported in previous studies 5, 14, 25 . This is likely because the cut off for follow up in our study was the end of 2017, which was later than other studies and therefore reflects the increasing availability of newer
INSTIs. For all INSTIs, the risk of discontinuation increased with later year of INSTI start, which may be related to the growing availability of post-marketing information on
AEs associated with INSTIs and greater availability of treatment options 2, 3, 14, [33] [34] [35] [36] .
Additionally, the risk of discontinuation was up to 3 times higher in Western Europe compared to other European regions, which may reflect the wider range of available treatment options in Western Europe 37 .
The risk of INSTI discontinuation was also higher for females compared to males. This is in line with studies carried out by Hoffman et al. 38 Our study has several limitations. Persons enrolled in RESPOND were not randomly selected as we pre-specified the minimum number of participants on INSTIs to be included in the cohort collaboration, and it is not possible to rule out confounding by indication or to fully adjust for all factors associated with choice and discontinuation of INSTIs. As is common with observational studies, there is a relatively high proportion of missing data, particularly for comorbidities. However, sensitivity analyses using multiple imputation to account for missing data showed similar results. Follow up for DTG in particular, may still be limited as the data cut-off for this analysis was the end of 2017. The reasons for discontinuation of INSTIs are those reported in patient notes and the proportion of unknown reasons, as well as the distribution of known reasons, differs considerably between cohorts. Only one reason was provided per discontinuation, and the reasons given are limited, for example, patient/physician choice may cover a wide range of reasons including concerns about toxicity, drug interactions, and adherence, however we did not have access to any further information. However, all cohorts used the HICDEP standard for reporting and have previously participated in the development of this standard. Finally, we did not collect data on non-antiretroviral treatment or pre-existing mental illness, which may affect the choice and discontinuation risk of INSTIs.
In conclusion, uptake of DTG compared to EVG/c or RAL has increased over calendar Treatment failure includes virological failure, immunological failure, clinical progression, death; if the discontinuation reason was reported as other causes or unknown and the viral load at discontinuation (± 3 months) was greater than 400 copies/mL, this was counted as treatment failure.
Simplified treatment available includes simplified treatment available, treatment too complex;
Toxicity includes abnormal fat redistribution, concern of cardiovascular, hypersensitivity reaction, abdomen or gastrointestinal tract toxicity, nervous system toxicity, kidney toxicity, endocrine system toxicity, unspecified side effects; Hypertension was confirmed by use of anti-hypertensives at any time before INSTI start or if the most recent blood pressure measurement before INSTI start was higher than 140/90 mmHg.
5
CVD was a centrally adjudicated event defined using a composite diagnosis of myocardial infarction, stroke or invasive cardiovascular procedure. 6 CKD was confirmed if there were two consecutive measurements of estimated glomerular filtration rate (eGFR) <60 mL/min measured at least 3 months apart. eGFR was calculated using the CKD-EPI creatinine equation (47) 
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